ARTL
Artelo Biosciences, Inc.NASDAQHealthcare$6.61-6.11%ClosedMarket Cap: $14.0M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-12.25
P/S
0.00
EV/EBITDA
-1.15
DCF Value
$-0.04
FCF Yield
-70.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1937.4%
ROA
-459.8%
ROIC
1969.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-2.8M | $-4.2M | $-2.04 | — |
| FY 2025 | $0.00 | NaN% | $-11.4M | $-12.9M | $-5.47 | — |
| Q3 2025 | $0.00 | NaN% | $-3.1M | $-3.1M | $-1.32 | — |
| Q2 2025 | $0.00 | NaN% | $-3.1M | $-3.2M | $-1.87 | — |
| Q1 2025 | $0.00 | NaN% | $-2.4M | $-2.4M | $-0.24 | — |
| Q4 2024 | $0.00 | NaN% | $-3.8M | $-3.8M | $-2.33 | — |
| FY 2024 | $0.00 | NaN% | $-10.1M | $-9.8M | $-1.02 | — |
| Q3 2024 | $0.00 | NaN% | $-1.2M | $-1.1M | $-0.12 | — |
| Q2 2024 | $0.00 | NaN% | $-2.5M | $-2.4M | $-0.25 | — |
| Q1 2024 | $0.00 | NaN% | $-2.6M | $-2.5M | $-0.26 | — |
| Q4 2023 | $0.00 | NaN% | $-3.2M | $-3.1M | $-1.93 | — |
| FY 2023 | $0.00 | NaN% | $-9.9M | $-9.3M | $-1.05 | — |